Brokerages Set Tempus AI, Inc. (NASDAQ:TEM) PT at $87.20

Tempus AI, Inc. (NASDAQ:TEM) has been given an average rating of “Hold” by the thirteen ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $87.20.

Several brokerages recently commented on TEM. Morgan Stanley raised their target price on Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Canaccord Genuity Group reduced their target price on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, December 22nd. Needham & Company LLC upped their target price on shares of Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, Piper Sandler lowered their price target on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th.

Insider Activity at Tempus AI

In other news, CFO James William Rogers sold 19,966 shares of Tempus AI stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $73.20, for a total transaction of $1,461,511.20. Following the sale, the chief financial officer directly owned 111,250 shares of the company’s stock, valued at approximately $8,143,500. The trade was a 15.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Erik Phelps sold 1,302 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $67.42, for a total value of $87,780.84. Following the completion of the transaction, the executive vice president owned 89,280 shares in the company, valued at approximately $6,019,257.60. This trade represents a 1.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 761,582 shares of company stock valued at $51,997,831. 26.27% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tempus AI

Hedge funds have recently bought and sold shares of the company. Cranbrook Wealth Management LLC bought a new position in Tempus AI during the 3rd quarter worth approximately $25,000. JPL Wealth Management LLC bought a new stake in shares of Tempus AI in the 3rd quarter valued at approximately $26,000. GAMMA Investing LLC acquired a new stake in shares of Tempus AI during the 3rd quarter valued at approximately $28,000. Concord Wealth Partners lifted its stake in Tempus AI by 308.0% during the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock worth $26,000 after purchasing an additional 308 shares during the last quarter. Finally, Allworth Financial LP boosted its holdings in Tempus AI by 5,000.0% in the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after purchasing an additional 450 shares during the period. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Stock Up 4.7%

Shares of NASDAQ TEM opened at $54.91 on Wednesday. Tempus AI has a 12-month low of $36.22 and a 12-month high of $104.32. The company has a market cap of $9.77 billion, a P/E ratio of -46.14 and a beta of 5.22. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. The stock has a fifty day moving average price of $66.36 and a 200 day moving average price of $73.75.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The company had revenue of $334.21 million for the quarter, compared to analysts’ expectations of $328.89 million. During the same quarter in the previous year, the firm posted ($0.46) earnings per share. The firm’s quarterly revenue was up 84.7% on a year-over-year basis. Research analysts anticipate that Tempus AI will post -6.15 EPS for the current fiscal year.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.